Document Detail

Experimental and clinical characteristics in myelodysplastic syndrome patients with or without HLA-DR15 allele.
MedLine Citation:
PMID:  19593744     Owner:  NLM     Status:  MEDLINE    
We studied the effects of the presence of the HLA-DR15 allele on the experimental and clinical features of myelodysplastic syndrome (MDS) by assessing the clinical data of 136 patients with MDS. We observed that the frequency of HLA-DR15 expression in MDS patients (38.7%) was significantly higher than that in the healthy controls (p < 0.01). We noted the following observations with regard to disease progression: None of the 46 HLA-DR15 positive patients with international prognostic scoring system (IPSS) scores <or=1 developed acute myeloid leukaemia (AML) during the follow-up period, while six of the 63 DR15-negative patients with the same IPSS score developed AML within a shorter follow-up period (p = 0.039). Furthermore, the incidence of poor chromosomal abnormalities, the percentage of patients with IPSS scores >or=1.5 and the presence of >or=5% blasts in the bone marrow in the DR15-positive patients were lower than the corresponding findings in the DR15-negative patients. In addition, we also recorded the following observations with regard to bone marrow (BM) failure: The bicytopenia/pancytopenia ratio in the DR15-positive patients was higher than that in the DR15-negative patients (92.4 vs. 78.3%; p = 0.029). The peripheral-neutrophil count and the platelet count in the DR15-positive patients were lower than those in the DR15-negative patients (p = 0.028 and p = 0.011, respectively). Moreover, hypocellularity was more easily detectable in the DR15-positive patients (26.4 vs. 16.9%). In addition, the BM CD4+ lymphocyte count and the CD4/CD8 ratio in the DR15-positive patients were higher than the corresponding values in the DR15-negative patients (p < 0.05 for both). However, there were no significant differences between the polarization of T-helper (T(h)) and T-cytotoxic (T(c)) cells and the cytokine levels in these two patient groups. We concluded that the presence of the HLA-DR15 allele is indicative of a genetic susceptibility to MDS and, the presence of the HLA-DR15 allele showed less association with disease progression and greater association with BM failure.
Li Xiao; Liao Qiong; Zhang Yan; Zhang Zheng; Song Luxi; Xu Li; Tao Ying; Liu Yizhi; Pu Quan
Related Documents :
20302964 - Frequency of cd4(+)cd25(hi)foxp3(+) regulatory t cells has diagnostic and prognostic va...
19332914 - An analysis of 30 cases of myelodysplastic syndrome.
20010464 - Frequency of bcr-abl gene mutations in polish patients with chronic myeloid leukemia tr...
6510404 - Red cell pyruvate kinase in acute leukemia.
1575454 - Transplantation of fetal dopamine neurons in parkinson's disease: one-year clinical and...
11020104 - Effect of risperidone on prolactinoma growth in a psychotic woman.
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  Hematological oncology     Volume:  28     ISSN:  1099-1069     ISO Abbreviation:  Hematol Oncol     Publication Date:  2010 Jun 
Date Detail:
Created Date:  2010-06-07     Completed Date:  2010-06-28     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8307268     Medline TA:  Hematol Oncol     Country:  England    
Other Details:
Languages:  eng     Pagination:  98-103     Citation Subset:  IM    
Copyright Information:
(c) 2009 John Wiley & Sons, Ltd.
Department of Hematology, Sixth Hospital affiliated to Shanghai Jiaotong University, Shanghai, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Asian Continental Ancestry Group / genetics
Bone Marrow / chemistry,  pathology
CD4 Lymphocyte Count
CD4-CD8 Ratio
Disease Progression
Gene Frequency
Genes, MHC Class II*
Genetic Predisposition to Disease
HLA-DR Antigens / genetics*
Interferon-gamma / analysis
Myelodysplastic Syndromes / blood,  genetics,  immunology*,  pathology
Tumor Necrosis Factor-alpha / analysis
Reg. No./Substance:
0/HLA-DR Antigens; 0/HLA-DR15; 0/Tumor Necrosis Factor-alpha; 82115-62-6/Interferon-gamma

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Two novel NPM1 mutations in a therapy-responder AML patient.
Next Document:  Investigating the role of attachment in social comparison theories of eating disorders within a non-...